세계의 항체 생산 시장 규모, 점유율, 동향 분석 : 제품별, 종류별, 프로세스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Antibody Production Market Summary

The global antibody production market size was estimated at USD 15.44 billion in 2024 and is projected to reach USD 39.80 billion by 2033, growing at a CAGR of 11.2% from 2025 to 2033. Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, coupled with the growing demand for therapeutic antibodies, has led to the rapid growth of the antibody production market.

Personalized and Next-Generation Antibodies

The global antibody production market is experiencing a significant shift as the industry moves beyond conventional monoclonal antibodies toward more complex, next-generation formats. Personalized therapies are increasingly becoming the standard of care, with bispecific antibodies, antibody-drug conjugates (ADCs), and engineered monoclonal antibodies emerging as critical tools in targeting diseases with greater precision and efficacy. These novel modalities not only enhance therapeutic outcomes but also open new opportunities for biopharmaceutical companies to differentiate their portfolios in an increasingly competitive landscape.

The rise of next-generation antibodies is fueling demand for advanced and highly specialized production technologies. Unlike traditional mAbs, which rely on relatively standardized production processes, bispecifics and ADCs require more sophisticated cell line development, purification techniques, and conjugation platforms. Manufacturers are rapidly adopting innovative solutions such as high-density perfusion bioreactors, modular single-use systems, and integrated continuous bioprocessing to meet these evolving requirements. This technological advancement is essential to achieve cost-effective scalability while maintaining the high quality and safety standards expected for complex biologics.

Market growth is further reinforced by strong investment flows from both established pharmaceutical players and emerging biotech firms aiming to capitalize on next-generation antibody pipelines. Partnerships, acquisitions, and capacity expansion initiatives are accelerating globally, with a particular focus on regions that are investing heavily in biopharma infrastructure. As regulatory frameworks evolve to accommodate these innovative therapies, companies that can align their production capabilities with the unique demands of personalized and next-generation antibodies are well positioned to capture a larger share of this expanding market. Ultimately, the convergence of scientific innovation, manufacturing excellence, and strategic investment is reshaping the antibody production landscape and sustaining robust long-term growth.

Global Antibody Production Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global antibody production market based on product, process, type, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
  • Bioreactors
  • Multi-use Bioreactors
  • Single-use bioreactors
  • Chromatography systems
  • Filtration systems
• Consumables
  • Media
  • Buffers and reagents
  • Chromatography resins and columns
  • Filtration consumables and accessories
  • Others
  • Software
• Process Outlook (Revenue, USD Million, 2021 - 2033)
• Upstream Processing
• Downstream Processing
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Monoclonal Antibody
• Polyclonal Antibody
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and biotechnology companies
• Research laboratories
• CROs and CDMOs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Production Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
    • 3.2.1.1. Increased demand for therapeutic antibodies
    • 3.2.1.2. Increasing investment in R&D
    • 3.2.1.3. Rise in adoption of antibody production for personalized medicine and companion diagnostics
  • 3.2.2. Market Restraint Impact Analysis
    • 3.2.2.1. Stringent government regulations
• 3.3. Industry Analysis Tools
  • 3.3.1. PESTEL Analysis
  • 3.3.2. Porter's Five Forces Analysis

Chapter 4. Antibody Production Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Antibody Production Market Product Movement Analysis
• 4.3. Global Antibody Production Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Global Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Bioreactors
    • 4.4.2.1. Global Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
    • 4.4.2.2. Multi-use Bioreactor
      • 4.4.2.2.1. Global Multi-Use Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
    • 4.4.2.3. Single-use Bioreactor
      • 4.4.2.3.1. Global Single-Use Bioreactors Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.4.3. Chromatography Systems
    • 4.4.3.1. Global Chromatography Systems Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.4.4. Filtration Systems
    • 4.4.4.1. Global Filtration Systems Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
• 4.5. Consumables
  • 4.5.1. Global Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Media
    • 4.5.2.1. Global Media Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.3. Buffers and Reagents
    • 4.5.3.1. Global Buffers and Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.4. Chromatography Resins and Columns
    • 4.5.4.1. Global Chromatography Resins and Columns Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.5. Filtration Consumables and Accessories
    • 4.5.5.1. Global Filtration Consumables and Accessories Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
  • 4.5.6. Others
    • 4.5.6.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Millions)
• 4.6. Software
  • 4.6.1. Global Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Antibody Production Market: Process Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Antibody Production Market Process Movement Analysis
• 5.3. Global Antibody Production Market Size & Trend Analysis, by Process, 2021 to 2033 (USD Million)
• 5.4. Upstream Processing
  • 5.4.1. Global Upstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Downstream Processing
  • 5.5.1. Global Downstream Processing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Antibody Production Market: Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Antibody Production Market Type Movement Analysis
• 6.3. Global Antibody Production Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 6.4. Monoclonal Antibody
  • 6.4.1. Global Monoclonal Antibody Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Polyclonal Antibody
  • 6.5.1. Global Polyclonal Antibody Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Antibody Production Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Antibody Production Market End Use Movement Analysis
• 7.3. Global Antibody Production Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Global Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Research Laboratories
  • 7.5.1. Global Research Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. CROs and CDMOs
  • 7.6.1. Global CROs and CDMOs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Antibody Production Market: Regional Estimates & Trend Analysis

• 8.1. Antibody Production Market: Region Outlook
• 8.2. North America
  • 8.2.1. North America Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Scenario
    • 8.2.2.4. U.S. Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Scenario
    • 8.2.3.4. Canada Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Scenario
    • 8.2.4.4. Mexico Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Scenario
    • 8.3.2.4. UK Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Scenario
    • 8.3.3.4. Germany Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Scenario
    • 8.3.4.4. France Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Scenario
    • 8.3.5.4. Italy Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Scenario
    • 8.3.6.4. Spain Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Scenario
    • 8.3.7.4. Denmark Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Scenario
    • 8.3.8.4. Sweden Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Scenario
    • 8.3.9.4. Norway Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. China
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Scenario
    • 8.4.2.4. China Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Scenario
    • 8.4.3.4. Japan Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Scenario
    • 8.4.4.4. India Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Scenario
    • 8.4.5.4. South Korea Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Scenario
    • 8.4.6.4. Australia Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Scenario
    • 8.4.7.4. Thailand Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Scenario
    • 8.5.2.4. Brazil Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Scenario
    • 8.5.3.4. Argentina Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Scenario
    • 8.6.2.4. South Africa Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Scenario
    • 8.6.3.4. Saudi Arabia Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Scenario
    • 8.6.4.4. UAE Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Scenario
    • 8.6.5.4. Kuwait Antibody Production Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Lonza Group
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Thermo Fisher Scientific, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. AGC Biologics
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Wuxi Biologics
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Charles River Laboratories
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Biointron
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Sartorius
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Eppendorf
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Merck KGaA
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives